Release time：Aug 27, 2019
On June 29, 2019, Mabwell (Shanghai) Bioscience Co., Ltd., participated in the 2nd symposium about the evaluation of immunogenicity which is sponsored by the Committee on Toxicology of Chinese Pharmacological Society at Jiangxi hotel, Beijing. Over 300 participants are joined and conference ended on June 30.
On behalf of Mabwell, Department of Pharmacology and Toxicology joined in the seminar. Department of Pharmacology and Toxicology is the main support Department for the whole process of new drug development. It is responsible for the pharmacology related work from project approval and drug early discovery to clinical stage in Mabwell biological R&D system.
The topics of this seminar included: Prediction of immunogenicity at early molecular screening stage; Non-clinical evaluation of immunogenicity detected in vitro; Early clinical immunogenicity risk control and clinical immunogenicity data interpreted to post-marketing therapeutic drug monitoring; Regulatory requirements, immunogenicity analysis methods to verify the clinical application.
